NEWS
Paul Hastings Advises BioMarin Pharmaceutical Inc. in Follow-On Public Offering
June 05, 2012
San Francisco, CA (June 5, 2012) - Paul Hastings LLP, a leading global law firm, announced today that the firm advised BioMarin Pharmaceutical Inc., a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten offering of 6,500,000 shares of common stock. In connection with launching the offering BioMarin estimated the offering would raise gross proceeds of approximately $249 million before costs.
BofA Merrill Lynch and Barclays acted as the underwriters in the offering.
Securities & Capital Markets partner Thomas Pollock led the Paul Hastings team, which also included corporate associates Samantha Eldredge and Aliza Cohen.
Paul Hastings LLP is a leading global law firm with offices in Asia, Europe, and the United States. We provide innovative legal solutions to financial institutions and Fortune 500 companies. Please visit www.paulhastings.com for more information.
Practice Areas
Securities and Capital Markets
SIGN UP FOR NEWS INSIGHTS
MEDIA CONTACTS
M&A, Private Equity, Data Privacy and Cybersecurity, Investment Funds and Private Capital, Structured Credit, Life Sciences, Employment Law and Media and Entertainment
Natalie GewargisAntitrust and Competition, Global Finance, Litigation, Financial Restructuring, Intellectual Property, Fintech and Payments, Consumer Financial Services, International Arbitration, and Investigations and White Collar Defense
Becca Hatton